| Andres Moon, MD | |
|
125 16th Ave E, Seattle, WA 98112-5211 | |
| (206) 326-3000 | |
| (206) 326-2785 |
| Full Name | Andres Moon |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 11 Years |
| Location | 125 16th Ave E, Seattle, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033552195 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | MD60723744 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kaiser Foundation Health Plan Of Washington | 9032022579 | 1480 |
News Archive
St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.
In homes across the country, there are dangerous products hidden in plain sight on bathroom counters and bedroom dressers.
Some patients refuse to answer. Many doctors don't ask. As the number of Americans with dementia rises, health professionals are grappling with when and how to pose the question: "Do you have guns at home?"
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
› Verified 5 days ago
| Entity Name | Kaiser Foundation Health Plan Of Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396810701 PECOS PAC ID: 9032022579 Enrollment ID: O20031112000454 |
News Archive
St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.
In homes across the country, there are dangerous products hidden in plain sight on bathroom counters and bedroom dressers.
Some patients refuse to answer. Many doctors don't ask. As the number of Americans with dementia rises, health professionals are grappling with when and how to pose the question: "Do you have guns at home?"
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andres Moon, MD 11511 Ne 10th St, Bellevue, WA 98004-8578 Ph: () - | Andres Moon, MD 125 16th Ave E, Seattle, WA 98112-5211 Ph: (206) 326-3000 |
News Archive
St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.
In homes across the country, there are dangerous products hidden in plain sight on bathroom counters and bedroom dressers.
Some patients refuse to answer. Many doctors don't ask. As the number of Americans with dementia rises, health professionals are grappling with when and how to pose the question: "Do you have guns at home?"
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype 1-infected patients.
› Verified 5 days ago
Afshin Shameli, MD, PHD Pathology Medicare: Medicare Enrolled Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-520-5000 | |
Dr. Mark Robert, Michael Kilgore, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, Box 356100, Seattle, WA 98195 Phone: 206-598-1821 Fax: 206-598-3803 | |
Corinne Lina Fligner, Pathology Medicare: Not Enrolled in Medicare Practice Location: University Of Washington Medical Ctr, 1959 Ne Pacific St, Seattle, WA 98195 Phone: 206-598-6400 | |
Jennifer Lapointe, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 1959 Ne Pacific St, C212, Box 356340, Seattle, WA 98195 Phone: 206-543-0065 | |
Lee-ching Zhu, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 125 16th Ave E, Seattle, WA 98112 Phone: 206-326-3000 | |
Dr. Saron Ann Elizabeth Smith, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 1229 Madison St Ste 820, Seattle, WA 98104 Phone: 206-576-6507 | |
Mr. Ryuji Ohashi, M.D. Pathology Medicare: Not Enrolled in Medicare Practice Location: Uwmc Pathology 1959 Ne Pacific, Box356100, Seattle, WA 98195 Phone: 206-598-7858 |